Nutraceuticals
IMCD to acquire Willows Ingredients to strengthen its food & nutrition offering throughout Ireland and the UK

IMCD N.V., a global leading partner for the distribution and formulation of speciality chemicals and ingredients, today announces it has signed an agreement to acquire 100% of the shares in Willows Ingredients Group Limited (Willows Ingredients), a distributor of ingredients serving the food and nutrition sector with expertise in health, sports and animal nutrition. The company predominantly serves customers across Ireland and the UK.

Willows Ingredients, headquartered in Ireland, will bring an established team of 26 employees and a long-standing reputation for technical support and strong customer relationships. In 2024, Willows Ingredients, reported revenues of approximately EUR 26 million.

The acquisition will expand IMCD’s existing presence in high-growth food and nutrition segments. Through the integration of Willows Ingredients’ supplier partnerships, IMCD will broaden its portfolio and market access to customers throughout Ireland and the UK.

Paul Hanbury, Managing Director, IMCD UK & Ireland, commented, “This acquisition represents an important step in developing our food & nutrition activities across the region. Willows Ingredients has built an impressive portfolio of nutrition ingredients, and the team brings long-standing trusted customer relationships and valuable expertise across Ireland and the UK. By combining their strengths with IMCD’s global reach and formulation capabilities, we can create even greater opportunities for our customers and principals.”

“We are proud of the strong customer relationships our team has built in the specialised nutrition space,“ said David Scrivens, Managing Director, Willows Ingredients. “By joining IMCD, we gain access to a global platform that will enable us to support our partners even more effectively. We look forward to contributing our knowledge and working alongside our new colleagues to deliver enhanced solutions for the market.”

The transaction is subject to customary closing conditions and is expected to close in the first quarter of 2026.